Groundbreaking Personal Protective Equipment
With the emergence and rapid spread of Covid-19 Coronavirus, we at Medi-Immune are working to bring our Personal Protective Equipment Device, ProtectivAir®, to the attention of key National and International decision makers, who can complete the development in the shortest possible timescales, so that Health Workers, First Responders and other critical groups, can be better protected during this pandemic.
What is ProtectivAir®
ProtectivAir® is a wearable, filter-free, breathing device that biologically sterilizes inhaled air, providing immediate protection against any airborne pathogen, even mutations.
If a pathogen has not yet been identified, or is a mutation of a known pathogen, ProtectivAir® will still protect. This allows time for the identification and subsequent production of a vaccine.
ProtectivAir® Patented Technology
Within the filter free irradiation chamber, energetic UVc photons pass through the infecting micro-organisms, damaging their nucleic acid (RNA or DNA) which disables their ability to replicate and infect the body.
The use of UVc in disinfection/decontamination is widely accepted and all published data confirms that UVc is an extremely effective germicidal agent.
Current Description – ProtectivAir®
Dimensions: 80 x 80 x 240mm
Power source: Battery or mains operated
Battery life: 4 hours, re-chargeable and interchangeable, with low charge warning indicator.
Usage: Re-useable device, 5+ year with maintenance
Cleaning: Internal self-sterilizing (external antibacterial wipe)
Contaminated waste: None (No filter required)
Portability: ProtectivAir® can be worn on a belt or harness
Users: Suitable for adults and children
Wearer Profile: First Responders, Health and Social Care, Key Educators, Key Public and Government services, Food and Pharmaceutical Supply, Transport, Key Utilities, Key Communication and Financial Services
Accessories: A comfortable, interchangeable, nose and mouth mask supplied with a flexible hose that attaches to the device
Protection Level: Using an example from viable Influenza A tests conducted at PHE, a 10-log reduction in viral particles is achieved at normal breathing rates i.e. less than 1 in 10,000,000,000 particles remains viable
Training: Minimal user training required